Related Experiment Video
Updated: Apr 28, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
DILI and drug development: a regulatory perspective
1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
Abstract:
The assessment of risk for serious, life-threatening drug-induced liver injury (DILI) associated with a suspect drug, biological agent, or herbal product depends on an iterative analysis of pre- and postmarket datastreams. Because serious cases of idiosyncratic DILI are typically rare, regulatory scientists seek strategies that accurately predict from clinical trial data which study drugs will be likely to cause these events in a large postmarket treatment population, e.g., through the identification of cases that are consistent with Hy's law. This objective is only achievable if rigorous standards in study subject monitoring, data collection and analysis of liver injury cases for causality are followed. In the future, the development of more effective predictive and analytic tools in preclinical and clinical testing will provide a framework to reliably identify new agents that have hepatotoxic profiles as well as those individuals who are susceptible to develop serious DILI.
Insights
Predicting rare, serious drug-induced liver injury (DILI) requires analyzing pre- and postmarket data. Rigorous monitoring and analysis are key to identifying hepatotoxic drugs and susceptible individuals.
Area of Science:
- Pharmacovigilance
- Hepatotoxicity
- Drug Safety
Background:
- Serious drug-induced liver injury (DILI) is rare but life-threatening.
- Predicting DILI risk from clinical trials is challenging due to data limitations.
- Identifying drugs causing idiosyncratic DILI is crucial for public health.
Purpose of the Study:
- To outline strategies for assessing DILI risk using pre- and postmarket data.
- To emphasize the importance of rigorous data collection and causality analysis for DILI cases.
- To highlight the need for improved predictive tools in drug development.
Main Methods:
- Iterative analysis of pre- and postmarket datastreams.
- Identification of cases consistent with Hy's law.
- Rigorous standards in subject monitoring and liver injury case analysis.
Main Results:
- Current methods rely on analyzing available data streams.
- Hy's law criteria aid in identifying potential hepatotoxic drugs.
- Adherence to rigorous standards is essential for accurate DILI assessment.
Conclusions:
- Accurate DILI risk assessment depends on robust data analysis and monitoring.
- Future predictive tools will enhance the identification of hepatotoxic agents.
- Identifying susceptible individuals is key to preventing serious DILI.
More Related Videos
11:36Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Related Concept Videos
Drug Regulation
Drug Toxicity: Overview
Drug Toxicity: Dose-Dependent Reactions
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug